60 completed. 60 Phase 2, 8 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 60 | Completed 60 |
| Phase 1 | 8 | Completed 8 |
| Phase 3 | 6 | Completed 6 |
Follow Dry Eye: new trials by email Literature Review of Dry Eye trials Research Report on Dry Eye
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preliminary Clinical Study of the Effectiveness and Safety of Ocular Surface Microbiota Transplantation in the Treatment of Dry Eye Disease Ocular surface microbiota transplantation, placebo transplantation - Dry Eye | Phase 1 / Phase 2 | Completed | Second Affiliated Hospital of Nanchang University | 30 | 2025-12-26 | 2026-10-16 |
| Phase 2b Controlled Study of Dosing Techniques - Part B IVW-1001 Ophthalmic Eyelid Wipe 0.2%, IVW-1001 Ophthalmic Eyelid Wipe 0.4% - Dry Eye | Phase 2 | Completed | IVIEW Therapeutics Inc. | 15 | 2025-09-08 | 2026-03-27 |
| Comparing Efficacy of Tea Tree Oil Versus Topical Azithromycin in Treating Dry Eye Tea Tree Oil Topical Application Oil, Azithromycin Ophthalmic Solution - Dry Eye | Phase 1 / Phase 2 | Completed | Ehab Mohamed Elsayed Mohamed Saad | 50 | 2025-03-01 | 2026-09-30 |
| Evaluation of BTV100 in Subjects With Dry Eye Disease BTV100 Low dose, BTV100 Mid dose, BTV100 High dose - Dry Eye | Phase 2 | Completed | BioTheraVision, Inc. | 123 | 2024-12-31 | 2026-10-07 |
| A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03. TTAX03, Saline (NaCl 0,9 %) (placebo) - Dry Eye, Dry Eye Disease (DED) | Phase 2 | Completed | BioTissue Holdings, Inc | 74 | 2024-12-12 | 2026-02-11 |
| Efficacy and Safety of Different Hyaluronic Acid Tear Substitutes Formulations in Evaporative Dry Eye Icross tear substitute, Hyabak tear substitute - Dry Eye | Phase 2 / Phase 3 | Completed | University of Seville | 30 | 2023-11-01 | 2024-07-26 |
| Efficacy and Safety of a Multiple-Action Tear Substitute (TriMix) in Dry Eye Disease Trimix tear substitutes, Hyaluronic acid tear substitute - Dry Eye | Phase 2 / Phase 3 | Completed | University of Seville | 124 | 2023-07-01 | 2024-06-27 |
| Study of OT202 in Treating Moderate to Severe Dry Eye OT202 conc 0.5%, OT202 conc 0.1%, Placebo - Dry Eye | Phase 2 | Completed | Ocumension Therapeutics (Shanghai) Co., Ltd | 213 | 2023-04-10 | 2024-05-30 |
| Clinical Evaluation of a Multidose Preservative-free Lubricating Eye Drops Contained in Novelia® Eye Dropper in Non-Contact Lens Wearing Patients Investigational Lubricating Eye Drop in a Novelia® bottle, Blink® Tears eye Drops - Dry Eye | Phase 2 | Completed | Johnson & Johnson Vision Care, Inc. | 121 | 2023-02-23 | 2025-04-27 |
| Efficacy of 0.38% and 0.18% Sodium Hyaluronate Ocular Lubricants for Dry Eye in Adult Gazan Participants 0.38% Sodium Hyaluronate (SH) Eye Drops, 0.18% Sodium Hyaluronate Eye Drops, Normal Saline Eye Drops - Dry Eye | Phase 2 | Completed | International Islamic University Malaysia | 45 | 2022-10-30 | 2025-03-03 |
| Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1) 0.3% YP-P10 Ophthalmic Solution, 1% YP-P10 Ophthalmic Solution, YP-P10 Placebo Ophthalmic Solution (vehicle) - Dry Eye | Phase 2 | Completed | Yuyu Pharma, Inc. | 257 | 2022-06-27 | 2024-07-30 |
| Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease. Sodium Hyaluronate Ophthalmic 0.4% one drop twice a day (BID), Sodium Hyaluronate Ophthalmic 0.4% one drop four times a day (QID), Sodium Hyaluronate Ophthalmic 0.4% Six times per day - Dry Eye | Phase 2 | Completed | Laboratorios Sophia S.A de C.V. | 141 | 2022-01-03 | 2026-03-03 |
| An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber Reproxalap Ophthalmic Solution (0.25%), Xiidra® (5% lifitegrast ophthalmic solution) - Dry Eye | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 56 | 2021-09-09 | 2025-02-28 |
| A Clinical Trial to Assess Subjects With Dry Eye Disease. Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Dry Eye | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 158 | 2021-06-15 | 2025-02-24 |
| ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease ALY688 Ophthalmic Solution - Dry Eye | Phase 2 / Phase 3 | Completed | Allysta Pharmaceutical | 922 | 2021-05-19 | 2023-03-16 |
| To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease OTX-DED - Dry Eye | Phase 2 | Completed | Ocular Therapeutix, Inc. | 172 | 2021-02-12 | 2023-02-22 |
| Detection of Acetylsalicylic Acid and Omega-3 Fatty Acids in Schirmers' Test Strips Using Mass Spectrometry Aspirin 500Mg Tab, Dr. Böhm® Omega 3 complex 870 mg - Dry Eye | Phase 2 | Completed | Medical University of Vienna | 32 | 2021-01-21 | 2023-03-20 |
| Study of VVN001 Ophthalmic Solution in Dry Eye Disease VVN001 Ophthalmic Solution 1%, VVN001 Ophthalmic Solution 5%, Vehicle - Dry Eye | Phase 2 | Completed | VivaVision Biotech, Inc | 169 | 2020-12-03 | 2023-12-13 |
| Clinical Trial to Compare the Safety and Efficacy of Nanodrop® Nanodrop®, Systane Balance - Dry Eye | Phase 1 / Phase 2 | Completed | Laboratorios Sophia S.A de C.V. | 126 | 2020-12-01 | 2025-07-16 |
| The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic Solution - Dry Eye, Dry Eye Syndromes | Phase 2 / Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 329 | 2020-11-21 | 2025-03-19 |
Showing 20 of 60. Sign in to see all of them.
Dry Eye Syndromes (60) · Sjogren's Syndrome (3) · Graft vs Host Disease (2) · Keratoconjunctivitis Sicca (2) · Xerophthalmia (2) · Arthritis, Rheumatoid (1) · Blepharitis (1) · Keratitis (1) · Lupus Erythematosus, Systemic (1) · Meibomian Gland Dysfunction (1) · Meibomitis (1) · Scleroderma, Diffuse (1)
Eye Diseases (60) · Lacrimal Apparatus Diseases (60) · Immune System Diseases (4) · Arthritis (3) · Autoimmune Diseases (3) · Conjunctival Diseases (3) · Connective Tissue Diseases (3) · Joint Diseases (3) · Mouth Diseases (3) · Musculoskeletal Diseases (3) · Rheumatic Diseases (3) · Salivary Gland Diseases (3) · Skin and Connective Tissue Diseases (3) · Stomatognathic Diseases (3) · Xerostomia (3)
Carboxymethylcellulose Sodium (2) · Doxycycline (2) · Ophthalmic Solutions (2) · lifitegrast (2) · Aspirin (1) · BID protein, human (1) · Brimonidine Tartrate (1) · Capsules (1) · Cyclosporins (1) · Dexamethasone (1) · Glycerol (1) · Hyaluronic Acid (1) · Immunoglobulins, Intravenous (1) · Loteprednol Etabonate (1) · Nerve Growth Factor (1)
Aldeyra Therapeutics, Inc. (4) · Santen Inc. (3) · Alcon Research (2) · Laboratorios Sophia S.A de C.V. (2) · Novartis Pharmaceuticals (2) · Ocular Therapeutix, Inc. (2) · Silk Technologies, Ltd. (2) · University of Seville (2) · Abbott Medical Optics (1) · Alacrity Biosciences, Inc. (1) · Alcon, a Novartis Company (1) · Allergan (1) · Allysta Pharmaceutical (1) · Aurinia Pharmaceuticals Inc. (1) · AxeroVision, Inc. (1)
United States (38) · China (4) · Australia (2) · Canada (2) · Mexico (2) · Spain (2) · Austria (1) · Chile (1) · Egypt (1) · Japan (1) · New Zealand (1) · Palestinian Territories (1) · Taiwan (1)
Gail Torkildsen, MD (5) · Anat Galor, MD, MSPH (1) · Cristhian A Urzua, MD (1) · Edmund K Waller, MD PhD (1) · Eric Donnenfeld, M.D. (1) · Eugene McLaurin, MD (1) · Gail L Torkildson, MD (1) · Giacomina Massaro Giordano, MD (1) · Jamie Christensen (1) · Jay H. Mashburn (1) · Jialu Xia (1) · Joel Naor, MD (1) · John Lonsdale, MD (1)
PMID 11879137, PMID 17508121, PMID 18848318, PMID 20735287, PMID 22330307, PMID 22670856, PMID 25826322, PMID 28777385, PMID 31373862, PMID 33096271, PMID 33561944, PMID 35192105, PMID 36586669, PMID 37077305, PMID 37209594, PMID 37478969, PMID 42764009, PMID 42803882, PMID 9894935